Search clinical trials for: cetuximab (Erbitux)

Total 3094 results

Prof. Dr. Andreas Engert
The Clinical Trials Centre Cologne

Terminated

EMMA-1 (Erbitux for Multiple Myeloma) (EMMA-1)

Multiple Myeloma

Germany
Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed

Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN (HNO-2)

Squamous Cell Carcinoma of the Hypopharynx Stage III | Squamous Cell Carcinoma of the Hypopharynx Stage IV | Squamous Cell Carcinoma of the Larynx Stage III | Squamous Cell Carcinoma of the Larynx Stage IV | Squamous Cell Carcinoma of the Oropharynx Stage III | Squamous Cell Carcinoma of the... and other conditions

Austria
RTOG Foundation, Inc.
Bristol-Myers Squibb

Completed

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Medical University of Vienna

Recruiting

Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure

Head and Neck Squamous Cell Carcinoma

Austria
Sanofi
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Oesophageal Adenocarcinoma | Oesophageal Squamous Cell Carcinoma

Korea, Republic of, Belgium, Italy, United States, Chile, China, France, Netherlands, Spain
UNC Lineberger Comprehensive Cancer Center
Pfizer; Amgen

Active, not recruiting

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Colon Cancer | Colonic Cancer | Cancer of the Colon | Colon Neoplasms | Neoplasms, Colonic

United States
Eli Lilly and Company

Completed

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States, Canada
Carmen Schade-Brittinger

Completed

Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer (ATIP)

Adenocarcinoma

Germany
US Oncology Research
Eli Lilly and Company; Oregon Health and Science University

Completed

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

Androgen-independent Prostate Cancer

United States
Dartmouth-Hitchcock Medical Center

Completed

Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer

Pancreatic Cancer
Baruch Brenner
Bristol-Myers Squibb; Merck Serono International SA

Recruiting

Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.

Esophageal Squamous Cell Carcinoma

Israel
Shanghai Changzheng Hospital

Recruiting

Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)

Colorectal Cancer

China
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
Pfizer

Completed

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Spain, Korea, Republic of, Czechia, Taiwan, Serbia, Japan, Slovakia, Mexico, Romania, Hungary, Italy, Poland, Russian Federation, Ukraine
University of Pittsburgh
Bristol-Myers Squibb

Completed

Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer

Cancer

United States
Sanofi
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

Squamous Cell Carcinoma of Head and Neck

Spain, Italy, United States, Chile, France, Argentina, Canada, Germany, Korea, Republic of, Netherlands, Taiwan
Per Pfeiffer
Odense University Hospital

Withdrawn

Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer (CECAVI)

Head and Neck Neoplasms

Denmark
Merck Sharp & Dohme LLC

Terminated

A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)

Rectal Neoplasms
University of Colorado, Denver

Completed

Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History

Squamous Cell Carcinoma of the Head and Neck

United States
National Cancer Institute (NCI)

Completed

BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer

Metastatic Colorectal Cancer

United States
Fox Chase Cancer Center

Terminated

Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

Colorectal Neoplasms

United States
State University of New York - Upstate Medical...
CTI BioPharma

Completed

A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

Carcinoma, Squamous Cell

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer

Anal Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer

Colorectal Cancer

United States
Jonathan Riess
National Cancer Institute (NCI)

Not yet recruiting

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Kathryn Gold
Pfizer

Active, not recruiting

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

United States
National Taiwan University Hospital

Unknown

Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer

Esophageal Cancer

Taiwan
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

Colorectal Cancer

United States
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaborators

Completed

A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC (BTC)

Cholangiocarcinoma | Adenocarcinoma of Gallbladder

Taiwan
Stanford University

Completed

Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Head and Neck Cancer

United States
Weill Medical College of Cornell University

Terminated

Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22

Glioblastoma Multiforme | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Brain Stem Glioma | Pilomyxoid Astrocytoma | Glioma of Brainstem | Fibrillary Astrocytoma of Brain | Mixed Oligodendroglioma-Astrocytoma

United States
Hans-Joachim Schmoll, MD
Biocompatibles UK Ltd

Terminated

TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer (DEBIRITUX)

Colorectal Cancer

Germany
Merrimack Pharmaceuticals
Sanofi

Completed

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Colorectal Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Squamous Cell Head and Neck Cancer | Other Tumors With EGFR Dependence

United States
Mahidol University

Active, not recruiting

Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma

Head and Neck Cancer | Locally Advanced

Thailand
Erasca, Inc.

Active, not recruiting

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)

Metastatic Colorectal Cancer | Metastatic Pancreatic Ductal Adenocarcinoma

United States
Institute of Oncology Ljubljana

Completed

Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer

Head and Neck Cancer

Slovenia
UNC Lineberger Comprehensive Cancer Center

Completed

Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca

Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer (ADCC)

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell... and other conditions

United States
Wangxia LV

Recruiting

Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC

Colorectal Cancer Metastatic

China
University of Miami

Terminated

Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma

Head and Neck Cancer | Recurrent Disease | Squamous Cell Carcinoma

United States
Eli Lilly and Company

Withdrawn

A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

United States
University of Chicago
Bristol-Myers Squibb

Terminated

Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Heath Skinner

Completed

SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

Squamous Cell Carcinoma of the Head and Neck Cancer | Previously-Irradiated

United States
US Oncology Research
Bristol-Myers Squibb; Pfizer

Active, not recruiting

PhII ICb With/Without Erbitux in MBC Pts (CA225200)

Metastatic Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Celgene Corporation

Completed

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
Arbeitsgemeinschaft medikamentoese Tumortherapie
Sanofi; Merck Sharp & Dohme LLC

Terminated

Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma

Esophageal Cancer

Austria
Merck KGaA, Darmstadt, Germany

Completed

A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck (CHANGE)

Squamous Cell Carcinoma of the Head and Neck

China, Korea, Republic of
Bristol-Myers Squibb

Completed

Phase I/II Combination With Irinotecan- Erbitux

Metastatic Colorectal Cancer (MCRC)

United States, Italy, Korea, Republic of, Spain, Sweden, Argentina, Denmark

Search clinical trials for: cetuximab (Erbitux)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations